Integrated Filing — IndAS



General information about company

Scrip Code 543427
NSE Symbol MEDPLUS
MSEI Symbol NOTLISTED
ISIN INE804L01022
Name of company Medplus Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 20-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment In accordance with Ind AS 108, Operating Segments, segment information has been given in the consolidated financial statements of MedPlus Health Services Limited and therefore no separate disclosure on segment information is given in these standalone financial statements
Start date and time of board meeting 20-05-2026   14:00:00
End date and time of board meeting 20-05-2026   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 03-08-2021
Indicate Company website link for updated RPT policy of the Company https://www.medplusindia.com/uploads/content/Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion Whether the company has any related party? Yes Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 24,803.60 86,056.60
Other income 248.60 1,076.60
Total income 25,052.20 87,133.20
2 Expenses
(a) Cost of materials consumed 1,813.60 8,124.10
(b) Purchases of stock-in-trade 17,363.00 57,038.50
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 13.50 71.90
(d) Employee benefit expense 1,471.10 5,429.90
(e) Finance costs 139.70 831.40
(f) Depreciation, depletion and amortisation expense 543.50 2,638.60
(f) Other Expenses
1 Other Expenses 1,402.20 4,681.50
Total other expenses 1,402.20 4,681.50
Total expenses 22,746.60 78,815.90
3 Total profit before exceptional items and tax 2,305.60 8,317.30
4 Exceptional items 0.00 0.00
5 Total profit before tax 2,305.60 8,317.30
6 Tax expense
7 Current tax 679.50 2,261.40
8 Deferred tax (41.10) (185.30)
9 Total tax expenses 638.40 2,076.10
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,667.20 6,241.20
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,667.20 6,241.20
17 Other comprehensive income net of taxes 37.50 37.50
18 Total Comprehensive Income for the period 1,704.70 6,278.70
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,401.10 2,401.10
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.39 5.21
Diluted earnings (loss) per share from continuing operations 1.39 5.2
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.39 5.21
Diluted earnings (loss) per share from continuing and discontinued operations 1.39 5.2
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the audited standalone financial results: 1.The above audited standalone financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 20, 2026. These financial results have been audited by the Statutory Auditors of the Company and the auditors have expressed an unqualified opinion on the same. 2.During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000.00 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below: Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to March 31, 2026 Unutilised amount as on March 31, 2026 i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii) General Corporate Purposes 1,117.63 1,117.63 - Total 5,789.33 5,789.33 - 3. During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the ‘New Labour Codes’, effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment. As a result of this plan amendment, the Company’s defined benefit obligation and defined benefit contribution increased by Rs. 1.58 and Rs. 0.47 respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss during the current year. The Company continues to monitor the Central / State Rules as notified and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 4.As per Ind AS 108 'Operating segments', the Company has disclosed the segment information as part of the consolidated financial results. 5.The results for the quarter ended March are the balancing amounts between the figures in respect of the full financial year and the published figures up to the third quarter of the respective financial year. 6.The earnings per equity share for the quarters are not annualised. 7.The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services Limited G. Madhukar Reddy Managing Director & Chief Executive Officer DIN: 00098097 Place: Hyderabad Date: May 20, 2026



Remarks

Debt equity ratio Debt to equity ratio is zero, since the Company doesn't have borrowings as at March 31, 2026 and March 31, 2025.
Debt service coverage ratio Debt Service Coverage ratio is zero, since the Company doesn't have borrowings as at March 31, 2026 and March 31, 2025.
Interest service coverage ratio Interest Service Coverage ratio is zero, since the company doesn't have any debt as on 31st March 2026


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 9,110.40
Capital work-in-progress 173.50
Investment property 0.00
Goodwill 0.00
Other intangible assets 92.20
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 93,064.40
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial assets 435.00
Total of other non-current financial assets 435.00
Total non-current financial assets 93,499.40
Deferred tax assets (net) 533.10
Other non-current assets
1 Right-of-use assets 7,489.80
2 Other tax assets 64.40
3 Other non-current assets 21.20
Total of other non-current assets 7,575.40
Total non-current assets 1,10,984.00
2 Current assets
Inventories 2,677.10
Current financial asset
Current investments 0.00
Trade receivables, current 13,260.60
Cash and cash equivalents 4,645.30
Bank balance other than cash and cash equivalents 9,258.60
Loans, current 0.00
Other current financial assets
Total of other current financial assets 4,707.60
Total current financial assets 31,872.10
Current tax assets (net) 0.00
Other current assets
1 Other current assets 966.30
Total of other current assets 966.30
Total current assets 35,515.50
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,46,499.50
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,401.10
Other equity 1,29,210.20
Total equity attributable to owners of parent 1,31,611.30
Non controlling interest
Total equity 1,31,611.30
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 8,427.20
Total of other non-current financial liabilities 8,427.20
Total non-current financial liabilities 8,427.20
Provisions, non-current 111.30
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 8,538.50
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 705.30
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,698.00
Total Trade payable 3,403.30
Other current financial liabilities
1 Lease liabilities 727.50
2 Other financial liabilities 495.50
Total of other current financial liabilities 1,223.00
Total current financial liabilities 4,626.30
Other current liabilities 1,331.00
1 Other current liabilities 221.50
2 Contract liabilities 1,109.50
Total of other current liabilities 1,331.00
Provisions, current 392.40
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 6,349.70
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 14,888.20
Total equity and liabilites 1,46,499.50
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain on net defined benefit plans 49.40 49.40
Total Amount of items that will not be reclassified to profit and loss 49.40 49.40
2 Income tax relating to items that will not be reclassified to profit or loss 11.90 11.90
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 37.50 37.50



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 8,317.30
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (844.80)
Adjustments for decrease (increase) in trade receivables, current 0.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (25.50)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (166.40)
Adjustments for other financial assets, current (905.90)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (117.40)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,638.60
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (129.40)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (721.20)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 896.40
Adjustments for share-based payments 63.60
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,140.70
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 35.90
Net cash flows from (used in) operations 8,353.20
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,155.50
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 6,197.70
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 1,654.80
Other cash payments to acquire equity or debt instruments of other entities 1,650.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 605.80
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 18,808.90
Purchase of other long-term assets 21,321.50
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 910.50
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (2,203.10)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 993.10
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 1,472.40
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (479.30)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 3,515.30
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 3,515.30
Cash and cash equivalents cash flow statement at beginning of period 1,130.00
Cash and cash equivalents cash flow statement at end of period 4,645.30





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R and Co Yes 30-04-2029


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 23-12-2021
Amount Raised 57,893.20
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Axis Bank Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details

Name of signatory Manoj Kumar Srivastava
Designation of person Company Secretary and Compliance Officer
Place Hyderabad
Date 20-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Sale of goods or services 97,257.90 Approved by AC 39,687.10 12,711.40 13,245.70
2 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Purchase of goods or services 20.00 Approved by AC 1.10 0.00 0.00
3 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Rendering of services 20.50 Approved by AC 15.70 0.00 0.00
4 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Management services 372.60 Approved by AC 137.80 0.00 0.00
5 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Brand fee 1,122.50 Approved by AC 514.50 0.00 0.00
6 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Availing of services 210.70 Approved by AC 103.80 0.00 0.00
7 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Leasing of property 243.10 Approved by AC 117.50 0.00 0.00
8 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Letting of property 103.80 Approved by AC 51.70 0.00 0.00
9 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Purchase of fixed assets 215.00 Approved by AC 68.90 0.00 0.00
10 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Sale of fixed assets 20.00 Approved by AC 0.00 0.00 0.00
11 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Payment made by MedPlus on behalf of Optival 10.00 Approved by AC 0.00 0.00 0.00
12 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Deemed Investment 349.00 Approved by AC 61.90 0.00 0.00
13 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Jobwork charges 25.00 Approved by AC 0.00 0.00 0.00
14 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Coupon collection received 350.00 Approved by AC 30.30 0.00 0.00
15 MedPlus Health Services Limited Optival Health Solutions Private Limited Subsidary Any other transaction Coupon collection paid 25.00 Approved by AC 0.10 0.00 0.00
16 MedPlus Health Services Limited Wynclark Pharmaceuticals Private Limited Subsidary Any other transaction Rendering of services 3.50 Approved by AC 1.70 0.30 0.20
17 MedPlus Health Services Limited Wynclark Pharmaceuticals Private Limited Subsidary Any other transaction Rendering of services 3.00 Approved by AC 0.20 0.00 0.00
18 MedPlus Health Services Limited Venkata Krishna Enterprises Private Limited Subsidary Any other transaction Share based payment expense 2.00 Approved by AC 0.50 0.00 0.00
19 MedPlus Health Services Limited Kalyani Meditimes Private Limited Subsidary Any other transaction Loan renewal (restructuring) 0.00 Approved by AC 0.00 178.20 178.20
20 MedPlus Health Services Limited Kalyani Meditimes Private Limited Subsidary Any other transaction Interest on Intercorporate Loans 32.00 Approved by AC 28.10 4.00 5.60
21 MedPlus Health Services Limited Sidson Pharma Distributors Private Limited Subsidary Any other transaction Share based payment expense 0.40 Approved by AC 0.10 0.00 0.00
22 MedPlus Health Services Limited MedPlus Insurance Brokering Private Limited Subsidary Any other transaction Rendering of services 5.00 Approved by AC 0.00 0.00 0.00
23 MedPlus Health Services Limited Clearancekart Private Limited Subsidary Any other transaction Rendering of services 2.00 Approved by AC 0.00 0.00 0.00
24 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Leasing of property 31.80 Approved by AC 0.00 0.00 0.00
25 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Purchase of Moulds 50.00 Approved by AC 0.00 12.50 12.50
26 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Maintenance of Moulds 26.00 Approved by AC 10.80 0.00 0.00
27 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Purchase of goods or services 5.00 Approved by AC 0.00 0.00 0.00
28 MedPlus Health Services Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Sub-lease in of Plastic factory 21.20 Approved by AC 16.30 0.00 0.00
29 MedPlus Health Services Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Purchase of goods or services 50.00 Approved by AC 0.00 0.00 0.00
30 MedPlus Health Services Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Maintenance of Moulds 17.30 Approved by AC 15.10 0.00 0.00
31 MedPlus Health Services Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Purchase of goods or services 5.00 Approved by AC 0.00 0.00 0.00
32 MedPlus Health Services Limited G. Madhukar Reddy Key Managerial personnel Remuneration 40.00 Approved by AC 20.00 0.00 18.70
33 MedPlus Health Services Limited G. Madhukar Reddy Key Managerial personnel Any other transaction Leasing of property 1.10 Approved by AC 0.50 0.00 0.00
34 MedPlus Health Services Limited C Bhaskar Reddy Key Managerial personnel Remuneration 141.80 Approved by AC 27.80 0.00 21.60
35 MedPlus Health Services Limited Sujit Kumar Mahato Key Managerial personnel Remuneration 143.80 Approved by AC 57.50 0.00 11.30
36 MedPlus Health Services Limited Sujit Kumar Mahato Key Managerial personnel Any other transaction Share based payment expense 43.40 Approved by AC 39.50 0.00 0.00
37 MedPlus Health Services Limited Manoj Kumar Srivastava Key Managerial personnel Remuneration 51.00 Approved by AC 21.90 0.00 3.90
38 MedPlus Health Services Limited Manoj Kumar Srivastava Key Managerial personnel Any other transaction Share based payment expense 13.90 Approved by AC 12.60 0.00 0.00
39 MedPlus Health Services Limited Madhavan Ganesan Independent director Remuneration 5.00 As per appointment Letter 5.00 0.00 0.00
40 MedPlus Health Services Limited Murali Sivaraman Independent director Remuneration 5.00 Approved by AC 5.00 0.00 0.00
41 MedPlus Health Services Limited Aparna Surabhi Independent director Remuneration 5.00 Approved by AC 5.00 0.00 0.00
42 MedPlus Health Services Limited Hiroo Mirchandani Independent director Remuneration 4.00 Approved by AC 0.00 0.00 0.00
43 MedPlus Health Services Limited Muralidharan Thyagarajan Independent director Remuneration 4.00 Approved by AC 4.00 0.00 0.00
44 MedPlus Health Services Limited MedPlus Employees group gratuity assurance scheme Fellow Subsidiary Any other transaction Employer contributions for Gratuity fund 100.00 Approved by AC 70.00 155.70 0.00
45 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Purchase of goods or services 4,000.00 Approved by AC 938.00 394.70 644.70
46 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Letting of property 2.60 Approved by AC 1.30 0.00 0.00
47 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Reimbursement of expenses 38.40 Approved by AC 24.70 0.00 0.00
48 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Rendering of services 31.10 Approved by AC 11.80 0.00 0.00
49 Optival Health Solutions Private Limited Sai Sridhar Pharma Private Limited Fellow Subsidiary Purchase of goods or services 46,438.40 Approved by AC 14,332.80 2,385.90 1,994.30
50 Optival Health Solutions Private Limited Sai Sridhar Pharma Private Limited Fellow Subsidiary Any other transaction Rendering of services 7.50 Approved by AC 2.80 0.00 0.00
51 Optival Health Solutions Private Limited Venkata Krishna Enterprises Private Limited Fellow Subsidiary Purchase of goods or services 51,930.00 Approved by AC 22,429.10 4,913.00 3,963.20
52 Optival Health Solutions Private Limited Venkata Krishna Enterprises Private Limited Fellow Subsidiary Any other transaction Rendering of services 11.20 Approved by AC 4.10 0.00 0.00
53 Optival Health Solutions Private Limited Deccan Medisales Private Limited Fellow Subsidiary Purchase of goods or services 15,308.70 Approved by AC 6,607.20 1,209.30 668.40
54 Optival Health Solutions Private Limited Deccan Medisales Private Limited Fellow Subsidiary Any other transaction Rendering of services 25.60 Approved by AC 9.40 0.00 0.00
55 Optival Health Solutions Private Limited Shri Banashankari Pharma Private Limited Fellow Subsidiary Any other transaction Reimbursement of claims 0.00 Approved by AC 0.00 0.60 0.60
56 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Purchase of goods or services 18,411.40 Approved by AC 6,027.70 1,137.90 920.60
57 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Any other transaction Reimbursement of claims 11.50 Approved by AC 5.10 0.00 0.00
58 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Any other transaction Rendering of services 4.40 Approved by AC 1.00 0.00 0.00
59 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Purchase of goods or services 150.00 Approved by AC 8.20 5.10 3.50
60 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Letting of property 0.30 Approved by AC 0.10 0.00 0.00
61 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Rendering of services 3.50 Approved by AC 0.90 0.00 0.00
62 Optival Health Solutions Private Limited Kalyani Meditimes Private Limited Fellow Subsidiary Any other transaction Letting of property 0.20 Approved by AC 0.10 0.10 0.20
63 Optival Health Solutions Private Limited Kalyani Meditimes Private Limited Fellow Subsidiary Any other transaction Rendering of services 0.80 Approved by AC 0.00 0.00 0.00
64 Optival Health Solutions Private Limited Medplus Insurance Brokers Private Limited Fellow Subsidiary Any other transaction Letting of property 2.50 Approved by AC 1.00 0.00 0.00
65 Optival Health Solutions Private Limited Medplus Insurance Brokers Private Limited entity controlling interest Any other transaction Letting of property 2.00 Approved by AC 0.20 0.00 0.00
66 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Any other transaction Letting of property 278.00 Approved by AC 0.30 0.10 0.10
67 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Any other transaction Letting of property 1.10 Approved by AC 0.00 0.00 0.00
68 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Purchase of goods or services 20.00 Approved by AC 0.00 0.00 0.00
69 Optival Health Solutions Private Limited G. Madhukar Reddy Key Managerial personnel Any other transaction Leasing of property 40.00 Approved by AC 20.10 0.00 0.00
70 Optival Health Solutions Private Limited Madhavan Ganesan Independent director Remuneration 3.80 Approved by AC 3.80 0.00 0.00
71 Optival Health Solutions Private Limited Aparna Surabhi Independent director Remuneration 3.80 Approved by AC 3.80 0.00 0.00
72 Optival Health Solutions Private Limited Optival Employees group gratuity assurance scheme Sister concern Any other transaction Employer contributions for Gratuity fund 1,350.00 Approved by AC 1,035.00 1,890.90 1,890.90
73 Optival Health Solutions Private Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Purchase of furniture and Job work for Furniture 162.90 Approved by AC 86.50 0.00 0.00
74 Optival Health Solutions Private Limited Gangadi Investments Private Limited Entities Over which share holders, key management personal exercise control or significant influence Purchase of goods or services 19.10 Approved by AC 0.00 0.00 0.00
75 Optival Health Solutions Private Limited Bhaskar Reddy Hospitals Directors relative is interested Any other transaction Profit Commission 66.00 Approved by AC 29.20 0.00 0.00
Total value of transaction during the reporting period 92,716.20